Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice

被引:127
作者
Guidetti, Paolo
Bates, Gillian P.
Graham, Rona K.
Hayden, Michael R.
Leavitt, Blair R.
MacDonald, Marcy E.
Slow, Elizabeth J.
Wheeler, Vanessa C.
Woodman, Ben
Schwarcz, Robert [1 ]
机构
[1] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA
[2] Kings Coll London, Guys Hosp, Dept Med & Mol Genet, London SE1 9RT, England
[3] Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V52 4H4, Canada
[4] Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA
[5] Massachusetts Gen Hosp, Ctr Human Genet Res, Charlestown, MA 02129 USA
基金
英国惠康基金;
关键词
excitotoxicity; free radicals; kynurenine monooxygenase; kynurenine pathway; microglia; neurodegeneration; NMDA;
D O I
10.1016/j.nbd.2006.02.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD). We now examined the status of these metabolites in three mouse models of HD. In R6/2 mice, 3-HK levels were significantly and selectively elevated in the striatum, cortex and cerebellum starting at 4 weeks of age. In contrast, both 3-HK and QUIN levels were increased in the striatum and cortex of the full-length HD models, beginning at 8 months (YAC128) and 15 months (Hdh(Q92) and Hdh(Q111)), respectively. No changes were seen in 13-month-old shortstop mice, which show no signs of motor or cognitive dysfunction or selective neuropathology. These results demonstrate both important parallels and intriguing differences in the progressive neurochemical changes in these HD mouse models and support the hypothesis that QUIN may play a role in the striatal and cortical neurodegeneration of HD. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 68 条
[1]   Huntingtin aggregation and toxicity in Huntington's disease [J].
Bates, G .
LANCET, 2003, 361 (9369) :1642-1644
[2]   REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[3]   Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria [J].
Brown, GC ;
Bal-Price, A .
MOLECULAR NEUROBIOLOGY, 2003, 27 (03) :325-355
[4]   PET-BASED AND MRI-BASED ASSESSMENT OF GLUCOSE-UTILIZATION, DOPAMINE-RECEPTOR BINDING, AND HEMODYNAMIC-CHANGES AFTER LESIONS TO THE CAUDATE-PUTAMEN IN PRIMATES [J].
BROWNELL, AL ;
HANTRAYE, P ;
WULLNER, U ;
HAMBERG, L ;
SHOUP, T ;
ELMALEH, DR ;
FRIM, DM ;
MADRAS, BK ;
BROWNELL, GL ;
ROSEN, BR ;
ISACSON, O .
EXPERIMENTAL NEUROLOGY, 1994, 125 (01) :41-51
[5]   Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release [J].
Choo, YS ;
Johnson, GVW ;
MacDonald, M ;
Detloff, PJ ;
Lesort, M .
HUMAN MOLECULAR GENETICS, 2004, 13 (14) :1407-1420
[6]   LESION OF STRIATAL NEURONS WITH KAINIC ACID PROVIDES A MODEL FOR HUNTINGTONS-CHOREA [J].
COYLE, JT ;
SCHWARCZ, R .
NATURE, 1976, 263 (5574) :244-246
[7]   Kynurenine hydroxylase inhibitors reduce ischemic brain damage:: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2YL]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia [J].
Cozzi, A ;
Carpenedo, R ;
Moroni, F .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1999, 19 (07) :771-777
[8]   SPARING OF CHOLINERGIC NEURONS FOLLOWING QUINOLINIC ACID LESIONS OF THE RAT STRIATUM [J].
DAVIES, SW ;
ROBERTS, PJ .
NEUROSCIENCE, 1988, 26 (02) :387-393
[9]   UPTAKE OF 3-HYDROXYKYNURENINE MEASURED IN RAT-BRAIN SLICES AND IN A NEURONAL CELL-LINE [J].
EASTMAN, CL ;
GUILARTE, TR ;
LEVER, JR .
BRAIN RESEARCH, 1992, 584 (1-2) :110-116
[10]   CYTO-TOXICITY OF 3-HYDROXYKYNURENINE IN A NEURONAL HYBRID CELL-LINE [J].
EASTMAN, CL ;
GUILARTE, TR .
BRAIN RESEARCH, 1989, 495 (02) :225-231